Roger Harrison to Recombinant Fusion Proteins
This is a "connection" page, showing publications Roger Harrison has written about Recombinant Fusion Proteins.
Connection Strength
2.847
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.559
-
Annexin-directed ß-glucuronidase for the targeted treatment of solid tumors. Protein Eng Des Sel. 2017 Feb; 30(2):85-94.
Score: 0.512
-
Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS One. 2013; 8(10):e76403.
Score: 0.410
-
Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Lett. 2011 Feb 28; 301(2):177-84.
Score: 0.339
-
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res. 2006 May-Jun; 26(3A):1745-51.
Score: 0.245
-
Discovery of new fusion protein systems designed to enhance solubility in E. coli. Methods Mol Biol. 2003; 205:141-54.
Score: 0.195
-
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Mol Cancer Ther. 2017 09; 16(9):1855-1865.
Score: 0.132
-
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. Pancreas. 2015 Aug; 44(6):945-52.
Score: 0.116
-
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett. 2011 Aug 01; 307(1):53-61.
Score: 0.087
-
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 2009; 84(5):271-5.
Score: 0.078
-
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Anticancer Res. 2007 Sep-Oct; 27(5A):3435-9.
Score: 0.067
-
A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties. Blood. 2006 Feb 01; 107(3):980-6.
Score: 0.059
-
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemother Pharmacol. 2003 Oct; 52(4):270-6.
Score: 0.050